A Phase I/II study of Lenalidomide and Obinutuzumab (GA101) in Relapsed Indolent Non-Hodgkin’s Lymphoma
The goal of this clinical research study is to find the highest tolerable dose of the combination of GA101 (obinutuzumab) and lenalidomide that can be given to patients with indolent NHL. The study will also look at how well the two drugs work together to control the disease.
Disease Group: Lymphoma
Treatment Agent: GA101,Lenalidomide
Treatment Location: Only at MDACC
Sponsor: Celgene,Genentech, Inc.
IRB Review and Approval Date: 05/21/2014
Recruitment Status: Open
Projected Accrual: N/A
Information and next steps
Phase I/Phase II
For general questions about clinical trials: